PRPH (ProPhase Labs) Cyclically Adjusted FCF per Share: $0.00 (As of Mar. 2026)


What is ProPhase Labs Cyclically Adjusted FCF per Share?

ProPhase Labs PRPH -13.04% Cyclically Adjusted FCF per Share is $0.00 as of Mar. 2026. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

ProPhase Labs's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.061. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.00 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -27.90% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -7.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -4.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of ProPhase Labs was 11.40% per year. The lowest was -145.80% per year. And the median was -21.30% per year.

As of today (2026-07-01), ProPhase Labs's current stock price is $0.08. ProPhase Labs's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $0.00. ProPhase Labs's Cyclically Adjusted Price-to-FCF of today is .


ProPhase Labs  (OTCPK:PRPH) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


ProPhase Labs Cyclically Adjusted FCF per Share Related Terms


ProPhase Labs Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for ProPhase Labs's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProPhase Labs Cyclically Adjusted FCF per Share Chart

ProPhase Labs Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.06 -1.41 -2.33 -3.10 -2.95

ProPhase Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.41 -3.30 -2.95 -2.95 0.00

PRPH vs IDTA, IVRO, FUNI: Cyclically Adjusted FCF per Share Comparison

For the Diagnostics & Research subindustry, ProPhase Labs's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProPhase Labs Cyclically Adjusted Price-to-FCF vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ProPhase Labs's Cyclically Adjusted Price-to-FCF falls into.



ProPhase Labs Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ProPhase Labs's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.061/330.2130*330.2130
=-0.061

Current CPI (Mar. 2026) = 330.2130.

ProPhase Labs Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.766 241.018 -1.049
201609 -0.440 241.428 -0.602
201612 0.097 241.432 0.133
201703 1.669 243.801 2.261
201706 -2.222 244.955 -2.995
201709 -0.322 246.819 -0.431
201712 -1.410 246.524 -1.889
201803 -0.145 249.554 -0.192
201806 0.114 251.989 0.149
201809 -1.127 252.439 -1.474
201812 -0.676 251.233 -0.889
201903 1.172 254.202 1.522
201906 -0.824 256.143 -1.062
201909 -0.865 256.759 -1.112
201912 -0.407 256.974 -0.523
202003 0.146 258.115 0.187
202006 3.736 257.797 4.785
202009 -0.479 260.280 -0.608
202012 -7.099 260.474 -9.000
202103 -6.494 264.877 -8.096
202106 2.727 271.696 3.314
202109 -3.590 274.310 -4.322
202112 -2.977 278.802 -3.526
202203 10.241 287.504 11.762
202206 2.152 296.311 2.398
202209 1.026 296.808 1.141
202212 -0.483 296.797 -0.537
202303 -0.023 301.836 -0.025
202306 -4.520 305.109 -4.892
202309 -3.098 307.789 -3.324
202312 -0.549 306.746 -0.591
202403 -3.490 312.332 -3.690
202406 -2.563 314.175 -2.694
202409 -2.116 315.301 -2.216
202412 -1.484 315.605 -1.553
202503 -0.960 319.799 -0.991
202506 -0.059 322.561 -0.060
202509 0.872 324.800 0.887
202512 -0.930 324.054 -0.948
202603 -0.061 330.213 -0.061

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $0.00 mean?
ProPhase Labs (PRPH) has a Cyclically Adjusted FCF per Share of $0.00 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on ProPhase Labs and its competitors.
Is ProPhase Labs' Cyclically Adjusted FCF per Share too high?
ProPhase Labs' current Cyclically Adjusted FCF per Share is $0.00.
How does ProPhase Labs' Cyclically Adjusted FCF per Share compare to IDTA and IVRO?
ProPhase Labs' Cyclically Adjusted FCF per Share of $0.00 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted FCF per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on ProPhase Labs and its competitors. ProPhase Labs's current Cyclically Adjusted FCF per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.65, compared to a current price of $0.08 — trading 87.7% below its estimated fair value. The current Cyclically Adjusted FCF per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current Cyclically Adjusted FCF per Share is $0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProPhase Labs Business Description

Address 626 RXR Plaza, 6th Floor, Uniondale, NY, USA, 11556
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.